Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis

Author(s): Bachert C


Recent advances in experimental immunologic approaches to seasonal allergic rhinitis (SAR) have led to a shift in the concepts of its pathogenesis. The conventional view of SAR as a local response to inhaled allergens has largely given way to a new view of this disorder as a systemic condition with local tissue manifestations. This concept, together with an increasing recognition of specific mediators' distinct roles in driving the early- and late-phase allergic responses, has opened multiple lines of therapeutic attack within the allergic cascade. Potent inhibition of inflammatory mediator release at distinct points in this cascade is conferred by desloratadine. In addition to the familiar range of SAR symptoms amenable to antihistamine therapy, desloratadine uniquely attenuates patient ratings of nasal congestion. This novel, nonsedating histamine H1-receptor antagonist is the only once-daily antiallergic product with a consistent decongestant effect that begins within hours of the first morning dose and is sustained for the entire treatment period.

Similar Articles

Burden of disease caused by otitis media: systematic review and global estimates

Author(s): Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, et al.

Antihistamine effects on experimental middle ear inflammatory model

Author(s): Chimona TS, Panayiotides JG, Papadakis CE, Helidonis ES, Velegrakis GA

Clinical practice guideline: Tympanostomy tubes in children

Author(s): Rosenfeld RM, Schwartz SR, Pynnonen MA, Tunkel DE, Hussey HM, et al.

Natural history of untreated otitis media

Author(s): Rosenfeld RM, Kay D

Otitis media

Author(s): Rovers MM, Schilder AG, Zielhuis GA, Rosenfeld RM

Action of inflammatory mediators on middle ear mucosa

Author(s): Dennis RG, Whitmire RN, Jackson RT